|
|
Article: Nanobac Pharmaceuticals Inc. Launches Landmark Study to Explore Heart Disease Properties of Calcifying Nanoparticles.
- Article from:
- Business Wire
- Article date:
- September 25, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla. -- Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") and Mayo Clinic have reached an agreement to study whether calcifying nanoparticles, already found in atherosclerotic plaque, are infectious and contribute to the onset of heart disease.
The identification of the cause of calcification would be a landmark in heart disease research. While many pathogens have been identified as a possible cause of calcification in the blood vessels of heart disease patients, to date, no smoking gun has been identified.
The study, "Nanoparticles and Arterial Calcification," will be led by Virginia Miller, Ph.D., with John Lieske, ...